Personalized cancer medicine for non-small cell lung cancer

我们利用裸鼠建立了一种可靠的、可重复的、简单的人肺癌细胞系原位模型，具有不同生物学和临床表型的多个模型可以更好地了解其行为和治疗效果。我们还发现了活检标本和IHC评估的手术标本之间生物标志物表达的相关性。最后，我们进行了一项联合egfr -酪氨酸激酶抑制剂和细胞毒性药物治疗复发性肺癌的I/II期临床研究。这些结果导致个体化化疗，并使晚期非小细胞肺癌患者受益。

We developed a reliable, reproducible, and simple orthotopic model for human lung cancer cell line using nude mice, multiple models with different biologic and clinical phenotypes may allow a better understanding of the behavior and treatment effects. We also showed correlation of the biomarker expression between biopsy specimens and surgical specimens assessed by IHC. Finally, we conducted a phase I/II clinical study of combination chemotherapy with EGFR-tyrosine kinase inhibitor and cytotoxic agent for recurrent lung cancer.These results lead to individualized chemotherapy and benefit patients with advanced non-small-cell lung cancer.